12:00 AM
Jul 20, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PF-04360365: Phase I data

Data from a double-blind, placebo-controlled, dose-escalation, Phase I trial in 37 patients showed that 0.1-10 mg/kg PF-04360365 was well tolerated. The most...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >